Kythera Biopharmaceuticals Inc. has reported positive interim results from a late-stage trial of its primary product, a drug designed to reduce chin fat.
The Calabasas biopharmaceutical company said at a medical conference on Saturday that 87 percent of the 165 patients in the trial saw reductions in chin fat. The company also said 97 percent of patients reported improvement in chin and neck definition.
The drug, ATX-101, is designed to reduce double chins through a series of injected treatments. Kythera has said it hopes to ask the FDA for approval later this year to begin marketing the drug next year.
“The results of this study suggest that microinjections of ATX-101 have an acceptable safety profile and can reduce the appearance of a double chin with high patient satisfaction,” said Susan Weinkle, a doctor who presented the study.
The company said it expects to report full findings from the trial in the next few months.
Kythera went public in October, raising $72.6 million. But last month it reported a wider-than-expected loss in the fourth quarter – $18 million – which it attributed to the cost of expanded trials.
Shares lost 71 cents, or 3.5 percent, to close at $19.64 on the Nasdaq.